CN115814005A - Natural plant vulva cleanser and preparation method and application thereof - Google Patents
Natural plant vulva cleanser and preparation method and application thereof Download PDFInfo
- Publication number
- CN115814005A CN115814005A CN202211585163.1A CN202211585163A CN115814005A CN 115814005 A CN115814005 A CN 115814005A CN 202211585163 A CN202211585163 A CN 202211585163A CN 115814005 A CN115814005 A CN 115814005A
- Authority
- CN
- China
- Prior art keywords
- extract
- cleanser
- natural plant
- oil
- vulvar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 210000003905 vulva Anatomy 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 164
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 98
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- -1 alkyl glycoside Chemical class 0.000 claims abstract description 42
- 229930182470 glycoside Natural products 0.000 claims abstract description 41
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 29
- 229940101267 panthenol Drugs 0.000 claims abstract description 29
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 29
- 239000011619 pantothenol Substances 0.000 claims abstract description 29
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 27
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 26
- 229960000458 allantoin Drugs 0.000 claims abstract description 26
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims abstract description 26
- 229940079988 potassium cocoyl glycinate Drugs 0.000 claims abstract description 24
- 235000005979 Citrus limon Nutrition 0.000 claims abstract description 22
- 244000131522 Citrus pyriformis Species 0.000 claims abstract description 22
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 22
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 22
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 22
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 22
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 22
- 241000220317 Rosa Species 0.000 claims abstract description 22
- 229940069521 aloe extract Drugs 0.000 claims abstract description 22
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 22
- 239000010634 clove oil Substances 0.000 claims abstract description 22
- 235000008995 european elder Nutrition 0.000 claims abstract description 22
- 238000003756 stirring Methods 0.000 claims abstract description 22
- 241000196324 Embryophyta Species 0.000 claims abstract description 21
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 21
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract description 21
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 21
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 21
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 21
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 21
- 240000006028 Sambucus nigra Species 0.000 claims abstract description 20
- 235000003142 Sambucus nigra Nutrition 0.000 claims abstract description 20
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims abstract description 18
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 18
- 239000010629 calamus oil Substances 0.000 claims abstract description 18
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 15
- 239000000341 volatile oil Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 235000011187 glycerol Nutrition 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 14
- 244000205574 Acorus calamus Species 0.000 claims description 9
- 235000006480 Acorus calamus Nutrition 0.000 claims description 9
- 239000010643 fennel seed oil Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000000419 plant extract Substances 0.000 claims description 8
- 238000007865 diluting Methods 0.000 claims description 5
- 241000382455 Angelica sinensis Species 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 235000014104 aloe vera supplement Nutrition 0.000 claims 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 18
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 5
- 230000003020 moisturizing effect Effects 0.000 abstract description 3
- 238000010790 dilution Methods 0.000 abstract description 2
- 239000012895 dilution Substances 0.000 abstract description 2
- 229960005150 glycerol Drugs 0.000 abstract description 2
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 24
- 239000006260 foam Substances 0.000 description 23
- 244000061520 Angelica archangelica Species 0.000 description 17
- 239000012153 distilled water Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000003385 bacteriostatic effect Effects 0.000 description 13
- 241000222122 Candida albicans Species 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- 229940095731 candida albicans Drugs 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 9
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000004088 foaming agent Substances 0.000 description 7
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000208829 Sambucus Species 0.000 description 2
- 235000018735 Sambucus canadensis Nutrition 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000007123 blue elder Nutrition 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000007124 elderberry Nutrition 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- DXDTUQXKMVJYAM-UHFFFAOYSA-N 2-aminoacetic acid;potassium Chemical compound [K].NCC(O)=O DXDTUQXKMVJYAM-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000009188 angelicae sinensis extract Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- GZWNUORNEQHOAW-UHFFFAOYSA-M potassium;2-aminoacetate Chemical compound [K+].NCC([O-])=O GZWNUORNEQHOAW-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a natural plant vulva cleanser and a preparation method and application thereof. The natural plant vulva cleanser consists of the following components: cucumber extract, sambucus nigra extract, lemon extract, plantain extract, rose extract, angelica extract, medlar extract, astragalus extract, aloe extract, clove oil, fennel calamus oil, alkyl glycoside, glycerol, potassium cocoyl glycinate, cocamidopropyl betaine, isomalto-oligosaccharide, panthenol, allantoin, disodium EDTA and water. The preparation method comprises the following steps: mixing and stirring alkyl glycoside, potassium cocoyl glycinate and cocamidopropyl betaine, adding essential oil, stirring uniformly, adding water for dilution, stirring until the mixture is clear, adding the rest materials, and stirring uniformly to obtain the final product. The prepared product has good moisturizing and antibacterial effects, and is mainly applied to vulva parts.
Description
Technical Field
The invention relates to the technical field of skin care products, in particular to a natural plant vulva cleanser as well as a preparation method and application thereof.
Background
Gynecological inflammation is a disease which is very concerned by women all the time, the onset time of gynecological inflammation is long, and certain differences exist due to different clinical manifestations of the disease. At present, a plurality of lotion for cleaning vulva are provided, most of which are Chinese patent medicine preparations, are prepared by decocting traditional Chinese medicines, and have certain bacteriostatic and bactericidal effects. But the bacteriostatic effect is not obvious and the curative effect is not clear, and many patients blindly use the vulva cleaning medicine without seeing the medicine property and the medicine effect, so that the effect is not good, and the disease can be aggravated. Bringing inconvenience to the work and life of the patient. In addition, the traditional product is usually provided with more preservatives and the like in the components to cause damage to human skin, side effects such as allergy, stimulation and the like can occur after being used by many people, so that people cannot pay attention to the side effects, the external vagina skin is not improved fundamentally, and the traditional product is inconvenient to use and has unobvious effect.
Therefore, the method has great significance for searching a vulva cleaning product with definite curative effect, obvious bacteriostatic effect and low toxic and side effect.
Disclosure of Invention
The invention aims to provide a natural plant vulva cleanser.
The invention also aims to provide a preparation method of the natural plant vulva cleanser.
The invention also aims to provide application of the natural plant vulva cleanser in skin care products.
The invention adopts the following technical scheme:
a natural plant vulva cleanser comprises the following raw materials in percentage by weight: 5 to 17 percent of plant extract, 0.1 to 0.7 percent of essential oil and 83 to 95 percent of auxiliary material.
Preferably, the natural plant vulva cleanser provided by the invention comprises the following raw materials in percentage by weight: 10.69% of plant extract, 0.39% of essential oil and 88.92% of auxiliary material.
The plant extract of the invention is composed of 1-3% of cucumber extract, 1-3% of elderberry extract, 1-3% of lemon extract, 1-3% of plantain extract, 1-3% of rose extract, 0.01-0.05% of angelica extract, 0.04-0.2% of medlar extract, 0.01-0.05% of astragalus extract and 0.25-0.8% of aloe extract.
Preferably, the plant extract consists of 2% of cucumber extract, 2% of sambucus nigra extract, 2% of lemon extract, 2% of plantain extract, 2% of rose extract, 0.03% of angelica extract, 0.13% of medlar extract, 0.03% of astragalus extract and 0.5% of aloe extract.
The essential oil of the invention consists of 0.12 to 0.6 percent of clove oil and 0.01 to 0.05 percent of fennel and acorus calamus oil.
Preferably, the essential oil of the invention consists of 0.36 percent of clove oil and 0.03 percent of fennel and calamus oil.
The auxiliary materials comprise 6-10% of alkyl glycoside, 1-5% of glycerol, 1-3% of potassium cocoyl glycinate, 0.5-1.5% of cocamidopropyl betaine, 0.5-1.5% of isomaltose hypgather, 0.1-0.5% of panthenol, 0.05-0.15% of allantoin, 0.05-0.15% of EDTA disodium and 62-86% of water.
Preferably, the auxiliary material consists of 8% of alkyl glycoside, 3% of glycerol, 2% of potassium cocoyl glycinate, 1% of cocamidopropyl betaine, 1% of isomaltooligosaccharide, 0.3% of panthenol, 0.1% of allantoin, 0.1% of disodium EDTA and 73.42% of water.
A preparation method of a natural plant vulva cleanser comprises the following steps: mixing and stirring alkyl glycoside, potassium cocoyl glycinate and cocamidopropyl betaine, adding clove oil and fennel and calamus oil, stirring uniformly, adding a proper amount of water, diluting and stirring until clarification, and adding a cucumber extract, a sambucus nigra extract, a lemon extract, a plantain extract, a rose extract, an angelica sinensis extract, a medlar extract, a astragalus extract, an aloe extract, glycerin, isomaltooligosaccharide, panthenol, allantoin, disodium EDTA and the rest water, and stirring uniformly to obtain the ointment.
The invention relates to an application of a natural plant vulva cleanser in preparing a medicine for preventing and/or treating bacterial infection of vulva parts; mainly acts on the mycosis caused by staphylococcus aureus, escherichia coli, candida albicans and pseudomonas aeruginosa.
The invention has the advantages that:
1. the preparation method is simple, and the prepared cleaning agent has good and stable foamability and fine and uniform foam; the prepared product is convenient to use, has few preservatives, no side effect, good moisturizing effect and very obvious bacteriostatic effect, and has a strong bacteriostatic action; has good prevention and treatment effects on bacterial diseases caused by staphylococcus aureus, escherichia coli, candida albicans and pseudomonas aeruginosa. Compared with the prior art, the preparation not only solves the problem of side effects such as allergy, irritation and the like caused by adding too much preservative in the medicine, but also defines the bacteriostatic curative effect of the product.
2. The invention is tested in advance, the dosage of distilled water, alkyl glycoside and glycerin with larger dosage form influence factor is inspected, and the result is that: (1) When the amount of the distilled water is 75ml, the solution is uniform and clear, and the medicine is fully dissolved; (2) when the dosage of the alkyl glycoside is 8g, the foam is fine and uniform; (3) The glycerol is 3g, and the foam is fine and uniform, the time is long, and the drug is well dissolved.
3. The invention carries out orthogonal test screening on the influence factors of the cleaning agent, and the result is as follows: the alkyl glycoside has the largest influence on the quality of the cleaning foaming agent, and the main factors of the three factorsThe order of the steps is as follows: alkyl glycoside > distilled water > glycerin, and the optimal dosage of the auxiliary material is A 2 B 2 C 2 Namely: the using amount of distilled water is 75mL, the using amount of alkyl glycoside is 8g, and the using amount of glycerol is 3g; because other auxiliary materials are added in the prescription to be used as a synergistic effect and a skin care conditioner, the dosage of the distilled water is adjusted slightly, and the optimal dosage of the auxiliary materials is obtained by comprehensively considering: the dosage of distilled water is 73.32mL, the dosage of alkyl glycoside is 8g, and the dosage of glycerin is 3g, so that the prepared foam is fine and uniform, and the moisture retention effect is optimal.
4. The product prepared by the method has the following result after the antibacterial performance test: the repeated experiments of 3 times show that the sample has 79.8 to 89.2 percent of antibacterial rate to large intestine, 99.8 to 99.9 percent of antibacterial rate to staphylococcus aureus, 98.1 to 99.2 percent of antibacterial rate to candida albicans and 51.3 to 67.7 percent of antibacterial rate to pseudomonas aeruginosa. The prepared sample has the inhibition effect on large intestine bacteriostasis, staphylococcus aureus, candida albicans and pseudomonas aeruginosa; has very obvious inhibiting effect on staphylococcus aureus and candida albicans.
Detailed Description
For better understanding of the present invention, the following examples are given for further illustration of the present invention, but the present invention is not limited to the following examples.
Example 1
Prescription: 2g of cucumber extract, 2g of sambucus nigra extract, 2g of lemon extract, 2g of plantain extract, 2g of rose extract, 0.03g of angelica extract, 0.13g of medlar extract, 0.03g of astragalus extract, 0.5g of aloe extract, 0.36g of clove oil, 0.03g of fennel sweet flag oil, 8g of alkyl glycoside, 3g of glycerol, 2g of potassium cocoyl glycinate, 1g of cocamidopropyl betaine, 1g of isomaltooligosaccharide, 0.3g of panthenol, 0.1g of allantoin, 0.1g of EDTA disodium and 73.42g of water.
Example 2
Prescription: 3g of cucumber extract, 3g of sambucus nigra extract, 3g of lemon extract, 3g of plantain extract, 3g of rose extract, 0.05g of angelica extract, 0.2g of medlar extract, 0.05g of astragalus extract, 0.8g of aloe extract, 0.6g of clove oil, 0.05g of fennel sweet flag oil, 10g of alkyl glycoside, 5g of glycerol, 3g of potassium cocoyl glycinate, 1g of cocamidopropyl betaine, 1g of isomaltooligosaccharide, 0.5g of panthenol, 0.15g of allantoin, 0.15g of EDTA disodium and 62.45g of water.
Example 3
Prescription: 1g of cucumber extract, 1g of sambucus nigra extract, 1g of lemon extract, 1g of plantain extract, 1g of rose extract, 0.01g of angelica extract, 0.04g of medlar extract, 0.01g of astragalus extract, 0.25g of aloe extract, 0.12g of clove oil, 0.01g of fennel sweet flag oil, 6g of alkyl glycoside, 1g of glycerol, 1g of potassium cocoyl glycinate, 0.5g of cocamidopropyl betaine, 0.5g of isomalto-oligosaccharide, 0.1g of panthenol, 0.05g of allantoin, 0.05g of EDTA disodium and 85.36g of water.
Example 4
Prescription: 1.5g of cucumber extract, 1.5g of sambucus nigra extract, 1.5g of lemon extract, 1.5g of plantain extract, 1.5g of rose extract, 0.02g of angelica extract, 0.06g of medlar extract, 0.02g of astragalus extract, 0.3g of aloe extract, 0.24g of clove oil, 0.02g of fennel calamus oil, 6g of alkyl glycoside, 1.5g of glycerol, 1.5g of potassium cocoyl glycinate, 0.8g of cocamidopropyl betaine, 0.8g of isomaltooligosaccharide, 0.2g of panthenol, 0.08g of allantoin, 0.08g of disodium EDTA and 80.88g of water.
Example 5
Prescription: 2.5g of cucumber extract, 2.5g of sambucus nigra extract, 2.5g of lemon extract, 2.5g of plantain extract, 2.5g of rose extract, 0.04g of angelica extract, 0.1g of medlar extract, 0.04g of astragalus extract, 0.35g of aloe extract, 0.48g of clove oil, 0.04g of fennel calamus oil, 8g of alkyl glycoside, 2g of glycerol, 2.5g of potassium cocoyl glycinate, 1.2g of cocamidopropyl betaine, 1.2g of isomaltooligosaccharide, 0.4g of panthenol, 0.12g of allantoin, 0.12g of disodium EDTA and 70.91g of water.
Example 6
Prescription: 3g of cucumber extract, 3g of sambucus nigra extract, 3g of lemon extract, 3g of plantain extract, 3g of rose extract, 0.03g of angelica extract, 0.13g of medlar extract, 0.03g of astragalus extract, 0.5g of aloe extract, 0.5g of clove oil, 0.03g of fennel sweet flag oil, 9g of alkyl glycoside, 4g of glycerol, 2.5g of potassium cocoyl glycinate, 1.2g of cocamidopropyl betaine, 1.2g of isomaltooligosaccharide, 0.45g of panthenol, 0.14g of allantoin, 0.14g of disodium EDTA and 65.15g of water.
Example 7
Prescription: 1.5g of cucumber extract, 1.5g of sambucus nigra extract, 1.5g of lemon extract, 1.5g of plantain extract, 1.5g of rose extract, 0.03g of angelica extract, 0.13g of medlar extract, 0.03g of astragalus extract, 0.5g of aloe extract, 0.2g of clove oil, 0.03g of fennel calamus oil, 6.5g of alkyl glycoside, 1.5g of glycerol, 1.5g of potassium cocoyl glycinate, 1g of cocamidopropyl betaine, 1g of isomaltooligosaccharide, 0.3g of panthenol, 0.1g of allantoin, 0.1g of disodium EDTA and 79.58g of water.
Example 8
Prescription: 2.5g of cucumber extract, 2.5g of sambucus nigra extract, 2.5g of lemon extract, 2.5g of plantain extract, 2.5g of rose extract, 0.03g of angelica extract, 0.13g of medlar extract, 0.03g of astragalus extract, 0.5g of aloe extract, 0.3g of clove oil, 0.02g of fennel and calamus oil, 7.5g of alkyl glycoside, 2.5g of glycerol, 2.5g of potassium cocoyl glycinate, 1g of cocamidopropyl betaine, 1g of isomaltooligosaccharide, 0.3g of panthenol, 0.1g of allantoin, 0.1g of disodium EDTA and 71.49g of water.
Example 9
Prescription: 2g of cucumber extract, 2g of sambucus nigra extract, 2g of lemon extract, 2g of plantain extract, 2g of rose extract, 0.01g of angelica extract, 0.04g of medlar extract, 0.03g of astragalus extract, 0.25g of aloe extract, 0.6g of clove oil, 0.05g of fennel sweet flag oil, 8.5g of alkyl glycoside, 3g of glycerol, 2g of potassium cocoyl glycinate, 1g of cocamidopropyl betaine, 1g of isomalto-oligosaccharide, 0.3g of panthenol, 0.1g of allantoin, 0.1g of disodium EDTA and 73.02g of water.
Example 10
Prescription: 1.5g of cucumber extract, 1.5g of sambucus nigra extract, 1.5g of lemon extract, 1.5g of plantain extract, 1.5g of rose extract, 0.03g of angelica extract, 0.13g of medlar extract, 0.03g of astragalus extract, 0.5g of aloe extract, 0.36g of clove oil, 0.03g of fennel calamus oil, 8g of alkyl glycoside, 3g of glycerol, 2g of potassium cocoyl glycinate, 1g of cocamidopropyl betaine, 1g of isomaltooligosaccharide, 0.3g of panthenol, 0.1g of allantoin, 0.1g of disodium EDTA and 75.92g of water.
Formulations of examples 1-10 were prepared according to the preparation of example 11
Example 11
The preparation method comprises the following steps: mixing alkyl glycoside, potassium cocoyl glycinate and cocamidopropyl betaine, adding oleum Caryophylli and fennel calamus oil, stirring, diluting with water, stirring to clarify, adding fructus Cucumidis Sativi extract, ramulus Sambuci Williamsii extract, fructus Citri Limoniae extract, herba plantaginis extract, flos Rosae Rugosae extract, radix Angelicae sinensis extract, fructus Lycii extract, radix astragali extract, aloe extract, glycerol, isomaltooligosaccharide, panthenol, allantoin, EDTA disodium, and the rest water, and stirring.
Comparative example 1
Prescription: 2g of cucumber extract, 2g of sambucus nigra extract, 2g of lemon extract, 2g of plantain extract, 2g of rose extract, 0.03g of angelica extract, 0.13g of medlar extract, 0.03g of astragalus extract, 0.5g of aloe extract, 8g of alkyl glycoside, 3g of glycerol, 2g of potassium cocoyl glycinate, 1g of cocamidopropyl betaine, 1g of isomalto-oligosaccharide, 0.3g of panthenol, 0.1g of allantoin, 0.1g of disodium EDTA and 73.81g of water.
The preparation method comprises the following steps: mixing and stirring alkyl glycoside, potassium cocoyl glycinate and cocamidopropyl betaine, adding water, diluting and stirring until the mixture is clear, adding cucumber extract, sambucus nigra extract, lemon extract, plantain extract, rose extract, angelica extract, medlar extract, astragalus extract, aloe extract, glycerin, isomaltooligosaccharide, panthenol, allantoin, EDTA disodium and the rest water, and stirring uniformly to obtain the product.
In order to further verify the effectiveness of the invention, a series of verification tests are carried out, specifically as follows:
1. screening test of formulations
1.1, traditional Chinese medicine extract: cucumber extract, elderberry extract, lemon extract, plantain extract, rose extract, angelica extract, medlar extract, astragalus extract and aloe extract. The risk coefficient of the selected traditional Chinese medicine extract is 1-2, and the traditional Chinese medicine extract is safe and can be used as an anti-inflammatory agent and a humectant in a prescription.
1.2, essential oil: clove oil, fennel and calamus oil. According to the reports of related documents, eugenol contained in clove oil has various effects of antibiosis, anti-inflammation, analgesia and the like; fennel and acorus calamus oil has the bacteriostatic effect.
1.3 the rest of the materials: alkyl glycoside, glycerol, potassium cocoyl glycinate, cocamidopropyl betaine, isomaltose hypgather, panthenol, allantoin, EDTA disodium and water.
According to literature, alkyl glycoside is taken as a surfactant, so that the foaming property is good, and the foam is rich and fine. Good solubility and good thickening ability. The cocoyl potassium glycinate is a synthetic anionic surfactant, and the kneaded foam is smooth and elastic and has abundant foam amount. Cocamidopropyl betaine is a zwitterionic surfactant. Has excellent stability under both acidic and alkaline conditions. The detergent has the advantages of small irritation, easy water dissolution, acid and alkali stability, more foams, strong detergency, excellent thickening property, softness, bactericidal property, antistatic property and hard water resistance. Can obviously improve the softness, conditioning and low-temperature stability of washing products.
Therefore, alkyl glycoside is selected as an indicator, and the potassium cocoyl glycinate and the cocamidopropyl betaine have a synergistic effect.
1.4 test methods
1.4.1 Single factor assay
According to the test, the foam fineness, the foam uniformity, the foam stabilization time and the solution clarity are used as evaluation indexes, distilled water is screened out to be used as a solvent, glycerin is used as a thickening agent, alkyl glycoside is used as a surfactant, orthogonal design is carried out according to a single-factor test result, and the optimal proportion of auxiliary materials is finally obtained.
1.4.2 orthogonal test
According to the single-factor test result, the distilled water (A), the alkyl glycoside dosage (B) and the glycerin dosage (C) are taken as three factors, three levels in the prescription range are selected for each factor to carry out orthogonal design, the foam fineness, the foam uniformity, the foam stabilizing time and the solution clarity of the cleaning foaming agent are comprehensively considered, and the optimal preparation process is screened out.
1.5 analysis of results
1.5.1 screening of adjuvants in the prescription
The test used distilled water as the solvent, taking into account the side effects of propylene glycol and ethanol. The thickening properties of the solution also affect the stability time and the degree of smoothness of the foam, so that glycerol is selected as the thickening agent. Wherein, not only plays a thickening role, but also plays a role in latent dissolution and moisture preservation. The type of surfactant also affects the stability and foaming ability of the foam. In the test, alkyl glycoside with relatively good foaming performance is selected as the surfactant after single factor investigation.
(1) And (5) inspecting the amount of the distilled water. According to the test results, see table 1. As a result: the amount of distilled water is 75ml because the solution is clear and the drug is dissolved sufficiently, and thus the amount of distilled water is 75ml.
Table 1 inspection of distilled water usage
(2) And (5) inspecting the dosage of the alkyl glycoside. According to the test results, see table 2. As a result: when the dosage of the alkyl glycoside is 8g, the foam is fine and uniform, so that the dosage of the alkyl glycoside is determined to be 8g.
TABLE 2 examination of alkylglycoside amounts
(3) And (5) inspecting the using amount of the glycerol. According to the test results, see table 3. As a result: the glycerol is 3g, the foam is fine, uniform and lasting, and the medicine is well dissolved.
TABLE 3 examination of the amount of glycerol
1.5.2 orthogonal experiments and results
(1) And (4) evaluating the index.
According to a single-factor test, the dosage of distilled water, alkyl glycoside and glycerin is a main influence factor of the performance of the foaming agent, a 3-factor 3-level orthogonal test is designed, and the comprehensive evaluation = foam fullness x 35% + foam fineness x 35% + foam duration x 30%.
TABLE 4 factor level table
TABLE 5 orthogonal test results Table
TABLE 6 results analysis of variance
The influence degree of each factor on the quality of the cleaning foaming agent can be judged through the visual analysis of tables 5-6, wherein the influence of the alkyl glycoside on the quality of the cleaning foaming agent is the largest, and the primary and secondary sequence of the three factors is as follows: b is more than A and more than C, and the optimal process of each factor can be judged according to the mean value, so that the optimal auxiliary material dosage is A 2 B 2 C 2 Namely: the dosage of distilled water is 75mL, the dosage of alkyl glycoside is 8g, and the dosage of glycerol is 3g.
1.5.3 determination of the amount of essential oils
According to a preliminary test, the essential oil has small influence on the properties of the skin care foaming agent and has influence on the greasiness degree. The test considers the greasiness when adding 0.12g to 0.6g of clove oil and 0.01g to 0.05g of fennel and calamus oil, and the result shows that the greasiness is light and meets the requirement when the total adding amount of the essential oil is 0.39g, namely 0.36g of clove oil and 0.03g of fennel and calamus oil.
1.5.4 examination of the amount of disodium EDTA
Disodium EDTA, as a bactericidal preservative, is used in an amount that does not significantly affect the results of the experiment, so that 0.1g disodium EDTA is tentatively used in the normal range in consideration of the cost.
1.5.5 examination of the amount of panthenol used
According to the data, the panthenol has the functions of moisturizing. The molecular diameter and molecular mass of panthenol are very small, and the panthenol can penetrate into skin barrier and can reach the stratum corneum of skin to carry water in the skin, thereby playing a role in replenishing water and keeping moisture. Meanwhile, panthenol has the effects of enhancing skin elasticity, improving rough skin and relieving skin itch, and is very friendly to sensitive muscles. The common dosage is about 0.1-0.5%, and the dosage of the panthenol selected by the invention is 0.3g.
1.5.6 examination of the amount of isomaltooligosaccharide
According to the data, isomaltose hypgather has moisture retention property. It also can promote growth of beneficial bacteria. The dosage of the isomaltose hypgather does not have obvious influence on the experimental result, so that the dosage of the isomaltose hypgather is 1g in a normal range in consideration of the cost.
1.5.7 examination of allantoin dosage
According to the data, the allantoin has the functions of absorption, moisture preservation and moistening. The dosage is about 0.1-0.2%. The present invention considers the cost problem, and the dosage is selected to be 0.1g.
1.5.8 optimal prescription and process
In summary, 8% of alkyl glycoside, 2% of cocoyl glycine potassium and 1% of cocamidopropyl betaine are mixed and stirred, 0.36% of clove oil and 0.03% of fennel and calamus oil are added and stirred uniformly, a proper amount of distilled water is added for dilution and stirring until clarification is achieved, and then 2% of cucumber extract, 2% of sambucus nigra extract, 2% of lemon extract, 2% of plantain seed extract, 2% of rose extract, 0.03% of angelica extract, 0.13% of medlar extract, 0.03% of astragalus extract, 0.5% of aloe extract, 3% of glycerol, 1% of isomaltooligosaccharide, 0.3% of panthenol, 0.1% of allantoin, 0.1% of disodium EDTA and the rest of distilled water are added and stirred uniformly, so as to obtain the allantoin.
The product is yellow brown liquid, no crystal precipitation occurs after standing for 1 week, and the sprayed foam is fine foam. The prepared cleaning foaming agent has safe and feasible preparation process, reasonable prescription and stable performance, and accords with the relevant regulations of 'Chinese pharmacopoeia' of 2020 edition.
2. Test for bacteriostatic properties
2.1 materials
2.1.1 sample: a sample manufactured by Guizhou Hongyu pharmaceutical Co., ltd. At a date of 20220318.
2.12 test bacteria: staphylococcus aureus (ATCC 6538), escherichia coli (8099), candida albicans (ATCC 10231), pseudomonas aeruginosa (ATCC 15442); provided by the general microbiological center of China Committee for culture Collection of microorganisms. The test uses the strains to culture 24h of fresh culture of nutrient agar slant at 37 ℃ in 3 rd to 8 th generation/culture of fresh culture of culture medium slant in sandcastle agar for 24h at 37 ℃ in 6 th to 8 th generation to prepare bacterial suspension.
2.1.3 Instrument: a constant temperature incubator and an autoclave.
2.1.4 reagents: phosphate buffer (PBS, 0.03mol/L, pH7.2), sterilized normal saline, nutrient/Sabouraud's agar medium.
2.2 methods
2.2.1 preparation of bacterial suspension according to the Disinfection technical Specification of the Ministry of health (2002 edition) 2.1.1.2.3; 2.1.1.9.3 preparation of fungal suspension; 2.1.11.3.2 testing method for bacteriostasis performance of dissoluble antibacterial product.
2.2.2 preparation of control samples: mixing and stirring alkyl glycoside, potassium cocoyl glycinate and cocamidopropyl betaine, adding water, diluting and stirring until the mixture is clear, adding cucumber extract, sambucus nigra extract, lemon extract, plantain extract, rose extract, angelica extract, medlar extract, astragalus extract, aloe extract, glycerin, isomaltooligosaccharide, panthenol, allantoin, EDTA disodium and the rest water, and stirring uniformly to obtain the product.
2.2.3 the test was repeated 3 times at a test temperature of 20 ℃. + -. 1.
2.3 results
Repeated experiments for 3 times show that the antibacterial rate of the sample to escherichia coli is as follows: the sample has 79.8 to 89.2 percent of antibacterial rate to large intestine, 99.8 to 99.9 percent of antibacterial rate to staphylococcus aureus, 98.1 to 99.2 percent of antibacterial rate to candida albicans and 51.3 to 67.7 percent of antibacterial rate to pseudomonas aeruginosa. See tables 7-10.
Table 7 results of the samples tested for the bacteriostatic properties of Escherichia coli
TABLE 8 results of the samples tested on the bacteriostatic property of Staphylococcus aureus
TABLE 9 results of the test of the bacteriostatic properties of the samples on Candida albicans
TABLE 10 results of the samples tested for the bacteriostatic properties of Pseudomonas aeruginosa
4. Conclusion
The sample prepared by the method has bacteriostatic action on staphylococcus aureus, escherichia coli, candida albicans and pseudomonas aeruginosa. The product of the invention has the antibacterial effect of spectrum, and has good prevention and treatment effects on bacterial diseases caused by staphylococcus aureus, escherichia coli, candida albicans and pseudomonas aeruginosa.
While the invention has been described in detail in the foregoing by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that certain changes and modifications may be made therein based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (10)
1. A natural plant vulva cleanser is characterized by comprising the following raw materials in percentage by weight: 5 to 17 percent of plant extract, 0.1 to 0.7 percent of essential oil and 83 to 95 percent of auxiliary material.
2. The natural plant vulvar cleanser according to claim 1, characterized in that it is composed of the following raw materials, by weight: 10.69% of plant extract, 0.39% of essential oil and 88.92% of auxiliary material.
3. The natural plant vulvar cleanser of claim 1, wherein the plant extract consists of 1-3% of cucumber extract, 1-3% of sambucus nigra extract, 1-3% of lemon extract, 1-3% of plantain extract, 1-3% of rose extract, 0.01-0.05% of angelica sinensis extract, 0.04-0.2% of medlar extract, 0.01-0.05% of astragalus extract and 0.25-0.8% of aloe extract.
4. The natural plant vulvar cleanser of claim 2, wherein said plant extract consists of 2% of cucumber extract, 2% of sambucus nigra extract, 2% of lemon extract, 2% of plantain extract, 2% of rose extract, 0.03% of angelica sinensis extract, 0.13% of lycium barbarum extract, 0.03% of astragalus extract and 0.5% of aloe vera extract.
5. The natural plant vulva cleanser of claim 1, wherein said essential oil consists of clove oil 0.12-0.6%, acorus calamus oil 0.01-0.05%.
6. The natural plant vulvar cleanser of claim 2, wherein said essential oil consists of clove oil 0.36%, acorus calamus oil 0.03%.
7. The natural plant vulvar cleanser according to claim 1, wherein the auxiliary materials consist of 6-10% of alkyl glycoside, 1-5% of glycerol, 1-3% of potassium cocoyl glycinate, 0.5-1.5% of cocamidopropyl betaine, 0.5-1.5% of isomalto-oligosaccharide, 0.1-0.5% of panthenol, 0.05-0.15% of allantoin, 0.05-0.15% of disodium EDTA and 62-86% of water.
8. The natural plant vulvar cleanser of claim 2, wherein said adjuvants consist of 8% alkyl glycoside, 3% glycerol, 2% potassium cocoyl glycinate, 1% cocamidopropyl betaine, 1% isomalto-oligosaccharide, 0.3% panthenol, 0.1% allantoin, 0.1% disodium EDTA, 73.42% water.
9. A process for the preparation of a natural plant vulvar cleanser according to any of claims 1 to 8, said process comprising: mixing and stirring alkyl glycoside, potassium cocoyl glycinate and cocamidopropyl betaine, adding clove oil and fennel and calamus oil, stirring uniformly, adding a proper amount of water, diluting and stirring until clarification, and adding a cucumber extract, a sambucus nigra extract, a lemon extract, a plantain extract, a rose extract, an angelica sinensis extract, a medlar extract, a astragalus extract, an aloe extract, glycerin, isomaltooligosaccharide, panthenol, allantoin, disodium EDTA and the rest water, and stirring uniformly to obtain the ointment.
10. The natural plant vulvar cleanser according to any one of claims 1 to 8, characterized in that it is used for preparing a medicine for preventing and/or treating bacterial infection of vulvar part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211585163.1A CN115814005B (en) | 2022-12-09 | 2022-12-09 | Natural plant vulva cleanser and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211585163.1A CN115814005B (en) | 2022-12-09 | 2022-12-09 | Natural plant vulva cleanser and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115814005A true CN115814005A (en) | 2023-03-21 |
| CN115814005B CN115814005B (en) | 2024-03-08 |
Family
ID=85546270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211585163.1A Active CN115814005B (en) | 2022-12-09 | 2022-12-09 | Natural plant vulva cleanser and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115814005B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829041A (en) * | 2010-04-30 | 2010-09-15 | 北京欧凯纳斯科技有限公司 | Sterilizing and itch-relieving gynaecological lotion |
| CN103565692A (en) * | 2013-09-11 | 2014-02-12 | 广东景兴卫生用品有限公司 | Cleaning care liquid containing various plant extracts and preparation process thereof |
| CN106038422A (en) * | 2016-07-26 | 2016-10-26 | 杨秀庆 | Washing composition and preparation method and application thereof |
| CN110302251A (en) * | 2019-07-19 | 2019-10-08 | 江苏省中国科学院植物研究所 | A kind of Chinese medicine composition and its purposes in preparation treatment gynaecological imflammation disease product |
| CN111481597A (en) * | 2020-05-08 | 2020-08-04 | 株洲千金药业股份有限公司 | Female herbal bacteriostatic care solution and preparation method thereof |
| CN113081928A (en) * | 2021-04-29 | 2021-07-09 | 云南赛森生物科技有限公司 | Plant bacteriostatic gel and preparation method and application thereof |
-
2022
- 2022-12-09 CN CN202211585163.1A patent/CN115814005B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829041A (en) * | 2010-04-30 | 2010-09-15 | 北京欧凯纳斯科技有限公司 | Sterilizing and itch-relieving gynaecological lotion |
| CN103565692A (en) * | 2013-09-11 | 2014-02-12 | 广东景兴卫生用品有限公司 | Cleaning care liquid containing various plant extracts and preparation process thereof |
| CN106038422A (en) * | 2016-07-26 | 2016-10-26 | 杨秀庆 | Washing composition and preparation method and application thereof |
| CN110302251A (en) * | 2019-07-19 | 2019-10-08 | 江苏省中国科学院植物研究所 | A kind of Chinese medicine composition and its purposes in preparation treatment gynaecological imflammation disease product |
| CN111481597A (en) * | 2020-05-08 | 2020-08-04 | 株洲千金药业股份有限公司 | Female herbal bacteriostatic care solution and preparation method thereof |
| CN113081928A (en) * | 2021-04-29 | 2021-07-09 | 云南赛森生物科技有限公司 | Plant bacteriostatic gel and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115814005B (en) | 2024-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109044915B (en) | Infant hip-protecting cream and preparation process thereof | |
| WO2008071245A1 (en) | Pharmaceutical preparation for the treatment of inflammatory diseases of the urogenital tract | |
| CN110755331B (en) | Antibacterial infant washing and caring preparation and application thereof | |
| CN105326707A (en) | Radix stemonae traditional Chinese medicine hand sanitizer and preparation method thereof | |
| Greenhouse et al. | Myotonia, myokymia, hyperhidrosis, and wasting of muscle | |
| Spies et al. | Increased 99mTc-polyphosphate muscle uptake in a patient with polymyositis: case report | |
| CN110840826A (en) | Nose blocking agent and preparation method thereof | |
| CN109758394A (en) | A kind of multiple-effect milky lotion and preparation method thereof containing camellia seed oil | |
| Nayak et al. | An in vitro study to determine the effect of Terminalia chebula extract and its formulation on Streptococcus mutans | |
| CN109010529A (en) | A kind of Traditional Chinese medicine bacteriostatic gelling agent for vagina nursing | |
| CN103816114B (en) | Ganoderma sinense polysaccharide oral liquid composition and preparation method thereof | |
| CN115814005B (en) | Natural plant vulva cleanser and preparation method and application thereof | |
| KR102312643B1 (en) | Bladder infusion composition containing chondroitin sulfate (20 MG/ML), hyaluronic acid (16 MG/ML) and phosphate buffer (PH 6.1-7.9) with increased storage stability for treating cystitis | |
| US9833488B2 (en) | Sensitization composition and method of use | |
| CN106166123A (en) | There is the skin care compositions of antiallergic itching-relieving efficacies, emulsion and preparation method thereof | |
| KR20170133714A (en) | Chinese medicine ointment | |
| CN104784627A (en) | Traditional Chinese medicine externally used film agent used for treatment surgical open or closed injury and preparation method thereof | |
| DE69729120T2 (en) | DRUG COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF FYBROMYALGIA AND CHRONIC TEMPTATION SYNDROME | |
| KR102312625B1 (en) | Bladder instillation composition containing chondroitin sulfate (4.5 MG/ML), hyaluronic acid (16 MG/ML) and phosphate buffer (PH 6.1-7.9) with increased storage stability for the treatment of cystitis | |
| CN100443093C (en) | AIDS treating medicine | |
| CN108653383A (en) | A kind of medical antipyretic analgesic hydrogel | |
| CN107468924A (en) | One kind washes ear fluid and preparation method thereof | |
| DE202017103288U1 (en) | Composition for the treatment of inflammatory diseases of the genitourinary tract in the form of a high-dose combination of active ingredients | |
| CN106074995A (en) | A kind of bactericidal composition for treating female sex organs inflammation and application thereof | |
| CN107334852B (en) | External itching relieving liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |